Search results
Results from the WOW.Com Content Network
On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without ...
(Reuters) - Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in ...
The analysts covering Vir Biotechnology, Inc. ( NASDAQ:VIR ) delivered a dose of negativity to shareholders today, by...
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis ...
Sotrovimab's development began in December 2019, at Vir Biotechnology when Vir scientists first learned of the initial COVID-19 outbreak in China. [18] Vir subsidiary Humabs BioMed had already compiled a library of frozen blood samples from patients infected with viral diseases, including two samples from patients infected with SARS-CoV-1. [18]
The treatment, sotrovimab, received an emergency use authorization from the U.S. Food and Drug Administration in May, while the European Union's drug regulator has also backed it. In a study of ...
In response to the COVID-19 pandemic in the Philippines, proposals have been made to set up a virology research facility in the country.The Department of Science and Technology (DOST), headed by Secretary Fortunato de la Peña, announced in May 2020 that the science agency submitted a proposal to establish the Virology Institute of the Philippines, which is meant to conduct research on viruses ...